

Non-consolidated Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 31, 2022

(All financial information has been prepared in accordance with the Generally Accepted Accounting Principles in Japan)

August 13, 2021

Company name: Perseus Proteomics Inc. Stock market listing: Tokyo Stock Exchange
 Security code: 4882 URL: <https://www.ppmx.com/en/>
 Representative: Takuya Yokokawa, President & CEO
 Contact: Shinichi Suzukawa, Board member, Head of Administrative Department TEL: +81-3-5738-1705
 Scheduled date to commence dividend payment: -
 Scheduled date to file Securities Report: August 13, 2021
 Preparation of supplementary material on financial results: No
 Holding of financial results presentation meeting: No (for institutional investors and analysts)

(Amounts below one million yen were rounded down.)

1. Financial Results for the three months ended June 30, 2021 (April 1, 2021 – June 30, 2021)

(1) Operating results

(% represents year-on-year changes.)

| | Net sales | | Operating income | | Ordinary income | | Profit | |
|-------------------------------------|-------------|---|------------------|---|-----------------|---|-------------|---|
| | million yen | % | million yen | % | million yen | % | million yen | % |
| Three months ended June 30, 2021 | 15 | - | (115) | - | (134) | - | (141) | - |
| June 30, 2020 | - | - | - | - | - | - | - | - |

| | Basic earnings per share | Diluted earnings per share |
|-------------------------------------|-----------------------------|-------------------------------|
| Three months ended June 30, 2021 | Yen (16.12) | yen - |
| June 30, 2020 | - | - |

(Note) 1. The Company had not prepared quarterly non-consolidated financial statements for the three months of the fiscal year ended March 31, 2021. Accordingly, no figures are shown for the three months ended June 30, 2020 and no percentage changes are shown for the three months ended June 30, 2021.

2. Diluted earnings per share is not shown although the Company has potential dilutive shares, as net loss per share was recorded.

(2) Financial position

| | Total assets | Net assets | Shareholders' equity ratio |
|----------------|--------------|-------------|----------------------------|
| As of | million yen | million yen | % |
| June 30, 2021 | 3,628 | 3,584 | 98.7 |
| March 31, 2021 | 1,118 | 1,083 | 96.6 |

(Reference) Shareholders' equity: As of June 30, 2021: 3,580 million yen As of March 31, 2020: 1,080 million yen

2. Cash dividends

| | Dividend | | | | |
|--|----------|--------|--------|----------|-------|
| | Q1-end | Q2-end | Q3-end | Year-end | Total |
| | Yen | Yen | Yen | Yen | Yen |
| FY ended March 31, 2021 | - | 0.00 | - | 0.00 | 0.00 |
| FY ending March 31, 2022 | - | - | - | - | - |
| FY ending March 31, 2022 (Forecast) | - | 0.00 | - | 0.00 | 0.00 |

(Note) Revision from the most recently announced dividend forecast: No

3. Financial results forecast for the fiscal year ending March 31, 2022 (April 1, 2021 - March 31, 2022)

(% represents year-on-year changes.)

| | Net sales | | Operating income | | Ordinary income | | Profit | | Basic earnings per share |
|-----------|-------------|-----|------------------|---|-----------------|---|-------------|---|-----------------------------|
| | million yen | % | million yen | % | million yen | % | million yen | % | yen |
| Full year | 70 | 3.3 | (564) | - | (583) | - | (625) | - | (57.16) |

(Notes) 1. Revision from the most recently announced financial results forecast: No

2. Basic earnings per share is calculated using average number of shares outstanding including newly issued 3,300,000 shares by public offering.

Notes

(1) Adoption of special accounting methods for preparation of quarterly financial statements: None

(2) Changes in accounting policies, changes in accounting estimates, and restatement

- | | |
|--|------|
| (i) Changes in accounting policies due to revisions to accounting standards and other regulations: | Yes |
| (ii) Changes in accounting policies due to other reasons: | None |
| (iii) Changes in accounting estimates: | None |
| (iv) Restatement: | None |

(3) Number of issued shares (common shares)

(i) Total number of issued shares at the end of the period (including treasury shares)

As of June 30, 2021: 11,686,400 shares

As of March 31, 2021: 8,386,400 shares

(ii) Number of treasury shares at the end of the period

As of June 30, 2021: - shares

As of March 31, 2021: - shares

(iii) Average number of shares outstanding during the period

As of June 30, 2021: 8,749,037 shares

As of June 30, 2020: - shares

* Average number of shares outstanding during the period as of June 30, 2020 is not shown as the Company had not prepared quarterly non-consolidated financial statements for the three months of the fiscal year ended March 31, 2021.

* Financial results reports are exempt from audit conducted by certified public accountants or an audit corporation.

* Proper use of financial results forecasts, and other special matters

The forward-looking statements, including financial results forecasts, contained in these materials are based on information currently available to Perseus Proteomics Inc. (hereinafter "the Company") and on certain assumptions deemed to be reasonable. Consequently, any statements herein do not constitute assurances regarding actual results by the Company. Actual business and other results may differ substantially due to various factors.

Contents

- 1. Qualitative information on quarterly non-consolidated business results2
 - (1) Explanation of business results2
 - (2) Explanation of business results forecast and other forecasts3
- 2. Non-consolidated financial statements.....4
 - (1) Statement of balance sheet4
 - (2) Statement of income5

1. Qualitative information on quarterly non-consolidated business results

(1) Explanation of business results

The global economy has been continuously affected by the COVID-19 pandemic. While vaccination has been proceeding, re-expansion of the disease by variants has been concerns to the society.

The medical industry, to which the Company belongs, has continued to face the important problems including measurement to such novel infectious diseases and establishment of therapies against the diseases with growing number of patients globally such as cancer and dementia. Under such circumstances, the Company has thrived to promote its business proactively, focusing on drug discovery area. The outline of the results of each business area are as follows:

1) Drug discovery

The Company has been proceeding with antibody development mainly in cancer field by utilizing its efficient antibody obtaining platforms in order to fulfill unmet medical needs. Among the candidate antibodies we have obtained during the search for seeds, we have selected antibodies against GPC3, CDH3 and transferrin receptor: the Company has four pipeline drugs against the three targets and has been developing a number of antibodies to be next therapeutic drug candidates following them. During the first quarter, there were no sales booked in drug discovery. The progress of each pipeline is as follows:

a. PPMX-T002

PPMX-T002 targets CDH3, which is considered to be a cell adhesion factor. FUJIFILM Corp., which made a licensing agreement with the Company in 2011, has been developing it as an anti-cancer drug with radioisotope (RI) labelled. In the phase I study conducted in the USA, it was confirmed that PPMX-T002 accumulated on cancer cells of patients. In one case, decrease in solid tumor size was confirmed. Since 2019, the phase I study expansion which is equal to the phase II study in Japan has been conducted in the increased patients at the maximum tolerable dose. Also, FUJIFILM Toyama Chemical Co., Ltd. has been conducting the phase I study in Japan since April 2020.

b. PPMX-T003

PPMX-T003, a unique human antibody targeting transferrin receptor (TfR), was obtained through our own screening technology, ICOS method. TfR is related to iron uptake into cells and is highly expressed on cancer cells that proliferate at a significant pace. When this antibody binds to TfR, it inhibits iron uptake into cancer cells, which provides anti-tumor effect of inhibiting cancer cell proliferation. As PPMX-T003 is expected to have therapeutic effects for various types of cancers, its development has been the main focus of the Company.

Other than cancer cells, TfR is highly expressed on erythroblasts, nucleated cells in bone marrow from which red blood cells derive. Therefore, the Company selected polycythemia vera (PV), a disease where red blood cells increase abnormally, as its first indication, expecting the function of PPMX-T003 to inhibit iron uptake would work effectively. The Company started the phase I study in Japan in November 2019 and confirmed its safety in healthy volunteers in March 2021. On May 31, 2021, the Company submitted a clinical trial notification in PV patients to Japan Agency for Medical Research and Development to complete the phase I study as a next step.

Also, the Company has been proceeding with joint research on drug discovery with Juntendo University, Nagoya University, Fujita Health University and Gunma University, in order to clarify its mechanism of action as a therapeutic drug for blood cancers including PV, AML and MM as well as solid tumor.

c. PPMX-T004

PPMX-T003 targets CDH3, the same target as PPMX-T002, with a concept of antibody drug conjugate (ADC). ADC is expected to have high clinical effects regardless of immune function status of patients, as it is able to kill the targeting cells specifically by letting the labelled drug in cells. Also, there is no restriction in facilities as it uses no RI. The development status is not disclosed due to the contract with the out-licensed partner.

d. PPMX-T001

PPMX-T001 targets GPC3 which is highly expressed on liver cancer. Chugai Pharmaceutical Co., Ltd. (Chugai) was provided the rights to register the patents in 2006 and has been developing it in 2 different forms of a drug for liver cancer: GC33 and ERY974. The former did not show clinical effects in monotherapy, however, Chugai published at a conference that its efficacy in patients was confirmed in the phase I study of combination use with atezolizumab, an immune checkpoint inhibitor. The latter is a bispecific antibody which is able to bind to two

different targets at the same time. Its phase I study started in the USA and Europe and ended in August 2019. The phase I study has been conducted in Japan. Also, Phase I study of combination use of ERY974 with atezolizumab and bevacizumab, an inhibitor of new blood vessels, started in Japan and Taiwan.

2) Antibody Research Support

There were no sales booked related to antibody research support in this period.

3) Antibody and Reagent sales

Sales of antibody and reagent for research were almost in line with the plan. The Company has also continued to develop the test kit for determining exacerbation risk of pneumonia caused by COVID-19 utilizing PTX3 measurement kit (blood inflammation marker).

As a result, sales of the first quarter ended June 30, 2021 were 15,799 thousand yen.

As for profits, operating loss was 115,855 thousand yen, ordinary loss was 134,707 thousand yen and net loss was 141,006 thousand yen. There is no impact on financial results caused by application of "Accounting Standard for Revenue Recognition" (ASBJ Statement No.29, revised on March 31, 2020), etc.

Segment information is omitted as the Company has a single business segment, the pharmaceutical business.

(2) Explanation of business results forecast and other forecasts

There is no change in business results forecast of the fiscal year ending March 31, 2022 from "Non-consolidated Summary of Financial Results for the Fiscal Year Ended March 31, 2021" announced on June 22, 2021.

2. Non-consolidated financial statements

(1) Statement of balance sheet

(thousand yen)

| | As of March 31, 2021 | As of June 30, 2021 |
|----------------------------------|----------------------|---------------------|
| Assets | | |
| Current assets | | |
| Cash and deposits | 1,069,300 | 3,589,825 |
| Accounts receivable - trade | 8,750 | 7,277 |
| Finished goods | 879 | 896 |
| Supplies | 1,036 | 1,038 |
| Prepaid expenses | 4,554 | 13,072 |
| Consumption taxes receivable | 21,907 | 6,854 |
| Other | 2,473 | 247 |
| Total current assets | 1,108,901 | 3,619,212 |
| Non-current assets | | |
| Property, plant and equipment | 0 | 0 |
| Intangible assets | 0 | 0 |
| Investments and other assets | 9,724 | 9,724 |
| Total non-current assets | 9,724 | 9,724 |
| Total assets | 1,118,626 | 3,628,936 |
| Liabilities | | |
| Current liabilities | | |
| Accounts payable-other | 21,906 | 31,187 |
| Accrued expenses | 8,588 | 6,124 |
| Income taxes payable | 2,774 | 5,850 |
| Deposits received | 1,643 | 1,746 |
| Total current liabilities | 34,912 | 44,910 |
| Total liabilities | 34,912 | 44,910 |
| Net assets | | |
| Shareholders' equity | | |
| Share capital | 604,000 | 1,924,660 |
| Capital surplus | 889,889 | 2,210,549 |
| Retained earnings | (413,216) | (554,223) |
| Total shareholders' equity | 1,080,673 | 3,580,986 |
| Share acquisition rights | 3,040 | 3,040 |
| Total net assets | 1,083,713 | 3,584,026 |
| Total liabilities and net assets | 1,118,626 | 3,628,936 |

(2) Statement of income

| | (thousand yen) |
|--|-------------------------------------|
| | Three months ended June 30, 2021 |
| Net sales | 15,799 |
| Cost of sales | 179 |
| Gross profit | <u>15,619</u> |
| Selling, general and administrative expenses | |
| Research and development cost | 69,805 |
| Other | 61,669 |
| Total selling, general and administrative expenses | <u>131,475</u> |
| Operating loss | <u>(115,855)</u> |
| Non-operating income | |
| Interest received | 3 |
| Other | 0 |
| Total non-operating income | <u>4</u> |
| Non-operating expenses | |
| Listing expenses | 9,531 |
| Taxes and dues | 9,244 |
| Foreign exchange losses | 80 |
| Total non-operating expenses | <u>18,856</u> |
| Ordinary loss | <u>(134,707)</u> |
| Extraordinary losses | |
| Impairment losses | 5,817 |
| Total extraordinary losses | <u>5,817</u> |
| Loss before income taxes | <u>(140,525)</u> |
| Income taxes – current | 481 |
| Total income taxes | <u>481</u> |
| Loss | <u>(141,006)</u> |